Onderneming Novartis AG

NOVN

CH0012005267

Farmaceutische producten

Analistenconsensus

Vakgebied

Verkoop per activiteit

Verkoop per regio

Managers

Besturend

Aandelenklasse

Aandeelhouders

Participaties

Bedrijfsgegevens

Bedrijven van de groep

Sector

Verkoop per activiteit

Verkoop per regio

Ratings voor Novartis AG

Herzieningen van WPA

Kwartaalwinst - Afwijkingspercentage

Sector Farmaceutische producten - Andere

Geschatte realtime Cboe Europe Andere beurzen 12:46:19 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
89,26 ^CHF	-0,82%		+4,45%	+5,27%

08:14	NOVARTIS AG : Jefferies herhaalt koopadvies voor het aandeel	ZD
24/04	NOVARTIS AG : BMO Capital blijft neutraal	ZM

Novartis AG is een van 's werelds leiders op het gebied van het ontwerpen, produceren en op de markt brengen van farmaceutische producten. De netto-omzet (exclusief beëindigde bedrijfsactiviteiten) kan als volgt worden uitgesplitst naar therapeutisch gebied
- oncologie (29,9%)
- immunologie (17,2%)
- cardiovasculaire, nier- en metabolische ziekten (14,1%);
- neurowetenschap (8,9%).
De resterende netto-omzet (29,9%) is afkomstig van contractproductie van farmaceutische producten.
Eind 2023 had Novartis AG wereldwijd 33 productielocaties.
De netto-omzet is geografisch als volgt verdeeld: Europa (33%), de Verenigde Staten (39,5%), Azië/Afrika/Australië (20,5%), Canada en Latijns-Amerika (7%).

Aantal werknemers: 76 057

CHF in miljoen	2022	Gewicht	2023	Gewicht	Delta
Established Brands 30,0 %	-	-	12 238	30,0 %	-
Oncology 29,9 %	-	-	12 213	29,9 %	-
Immunology 17,2 %	-	-	7 008	17,2 %	-
Cardiovascular, Renal and Metabolic 14,1 %	-	-	5 743	14,1 %	-
Neuroscience 8,9 %	-	-	3 633	8,9 %	-

CHF in miljoen	2022	Gewicht	2023	Gewicht	Delta
United States 39,5 %	16 860	34,9 %	16 139	39,5 %	-4,28%
Europe 18,9 %	10 469	21,7 %	7 704	18,9 %	-26,41%
Asia/Africa/Australasia 9,1 %	4 975	10,3 %	3 700	9,1 %	-25,63%
Germany 7,4 %	4 086	8,5 %	3 026	7,4 %	-25,94%
China 7,2 %	2 987	6,2 %	2 936	7,2 %	-1,73%
Canada and Latin America 7,0 %	3 709	7,7 %	2 854	7,0 %	-23,04%
Japan 4,2 %	2 106	4,4 %	1 729	4,2 %	-17,90%
France 3,8 %	2 156	4,5 %	1 572	3,8 %	-27,09%
Switzerland 2,9 %	926	1,9 %	1 175	2,9 %	+26,88%

Managers	Titel	Leeftijd	Van
Vasant Narasimhan CEO	Chief Executive Officer	48	01-01-05
Harry Werner Kirsch DFI	Director of Finance/CFO	59	01-01-03
Shreeram Aradhye CTO	Chief Tech/Sci/R&D Officer	62	16-05-22
Steffen Lang COO	Chief Operating Officer	57	01-04-17
Klaus Moosmayer CMP	Compliance Officer	56	01-12-18
Samir Shah IRO	Public Communications Contact	63	01-01-04
Simon Brown PRN	Corporate Officer/Principal	-	01-08-13
Kees Roks AUD	Comptroller/Controller/Auditor	61	01-05-22
Linda Kanitra PRN	Corporate Officer/Principal	-	-
Robert Kowalski HRO	Human Resources Officer	56	01-09-21

Besturend	Titel	Leeftijd	Van
Bill Winters BRD	Director/Board Member	62	01-01-13
Simon Moroney BRD	Director/Board Member	65	28-02-20
Hans Jörg Reinhardt CHM	Chairman	68	01-01-13
John Young BRD	Director/Board Member	60	07-03-23
Bridgette Heller BRD	Director/Board Member	62	28-02-20
Ton Büchner BRD	Director/Board Member	59	01-01-16
Charles Sawyers BRD	Director/Board Member	65	01-01-13
Nancy Andrews BRD	Director/Board Member	65	01-01-15
Patrice Bula BRD	Director/Board Member	68	28-02-19
Frans van Houten BRD	Director/Board Member	64	28-02-17

	Stemming	Aantal	Vrij verhandelbaar	Bedrijfseigen aandelen	Drijvend Totaal
Aandeel A	1	2 189 930 497	1 866 336 959 ( 85,22 %)	233 443 766 ( 10,66 %)	85,22 %

Naam	Aandelen	%	Totale waarde
NOVARTIS AG 6,625 %	145 083 991	6,625 %	14 073 M CHF
Sandoz Family Foundation 4,070 %	89 135 960	4,070 %	8 646 M CHF
UBS Asset Management Switzerland AG 3,123 %	68 391 910	3,123 %	6 634 M CHF
Universal-Investment-Gesellschaft mbH (Invt Mgmt) 0,3011 %	6 593 896	0,3011 %	640 M CHF
State Street Global Advisors Ltd. 0,2103 %	4 604 889	0,2103 %	447 M CHF
UBS AG (Investment Management) 0,1782 %	3 902 170	0,1782 %	379 M CHF
La Mondiale SAM (Investment Portfolio) 0,1776 %	3 888 630	0,1776 %	377 M CHF
MFS International (UK) Ltd. 0,1769 %	3 873 030	0,1769 %	376 M CHF
MFS International Singapore Pte. Ltd. 0,1715 %	3 755 587	0,1715 %	364 M CHF
Union Investment Privatfonds GmbH 0,1659 %	3 632 402	0,1659 %	352 M CHF

Naam	Aandelen	%	Totale waarde
Dodge & Cox 0,6012 %	13 165 538	0,6012 %	1 274 M CHF
PRIMECAP Management Co. 0,5893 %	12 905 697	0,5893 %	1 248 M CHF
Eaton Vance Management 0,3239 %	7 092 253	0,3239 %	686 M CHF
Dimensional Fund Advisors LP 0,2776 %	6 078 175	0,2776 %	588 M CHF
Loomis, Sayles & Co. LP 0,2744 %	6 009 900	0,2744 %	581 M CHF
Fiduciary Trust Company International 0,2701 %	5 915 750	0,2701 %	572 M CHF
U.S. Trust Company of Delaware 0,2401 %	5 258 331	0,2401 %	509 M CHF
Wellington Management Co. LLP 0,2167 %	4 746 599	0,2167 %	459 M CHF
Wells Fargo Bank NA 0,1824 %	3 994 934	0,1824 %	386 M CHF
The Ayco Co. LP 0,1615 %	3 535 902	0,1615 %	342 M CHF

Naam	Aandelen	%	Totale waarde
LUKB Expert Fondsleitung AG -	64 694	-	6 M CHF
ATP Fondsmaeglerselskab A/S -	46 082	-	4 M CHF
Swiss Rock Asset Management AG -	19 614	-	2 M CHF
Niederer & Partners AG -	5 300	-	513 818 CHF
JPMorgan Asset Management (China) Co Ltd. -	2 652	-	257 103 CHF
Liontrust Portfolio Management Ltd. -	474	-	45 953 CHF

Naam	Aandelen	%	Totale waarde
NOVARTIS AG 6.63%	145 083 991	6.63%	14 073 485 173 $
SANDOZ GROUP AG 4.30%	18 524 209	4.30%	559 613 390 $
MORPHOSYS AG 11.57%	4 360 100	11.57%	316 438 618 $
NOVARTIS INDIA LIMITED 70.68%	17 450 680	70.68%	215 208 068 $
ERASCA, INC. 8.15%	12 307 692	8.15%	25 353 846 $
THIRD HARMONIC BIO, INC. 6.49%	2 642 762	6.49%	24 947 673 $
OCULIS HOLDING AG 4.68%	1 713 521	4.68%	20 647 928 $
POSEIDA THERAPEUTICS, INC. 6.12%	5 908 089	6.12%	18 846 804 $
MOLECULAR PARTNERS AG 4.78%	1 739 130	4.78%	7 095 929 $
PRECISION BIOSCIENCES, INC. 6.30%	413 577	6.30%	5 608 104 $

Novartis AG

Lichtstrasse 35

4056, Basel

+41 61 324 1111

http://www.novartis.com

Naam	Categorie en sector
Novartis International AG Novartis International AG Pharmaceuticals: MajorHealth Technology Novartis International AG manages the Novartis Group. It provides administrative, financial, legal, and technical services. It also offers scientific consultation to the Group. The company was founded on December 13, 1989 and is headquartered in Basel, Switzerland.	Pharmaceuticals: Major
Novartis BioVenturesAG Novartis BioVenturesAG Investment ManagersFinance Part of Novartis AG, Novartis BioVenturesAG is an alternative investment manager. The private company is based in Basel, Switzerland.	Investment Managers
NOVARTIS INDIA LIMITED	Pharmaceuticals: Major
Novartis Securities Investment Ltd. Novartis Securities Investment Ltd. Investment ManagersFinance Part of Novartis AG, Novartis Securities Investment Ltd. is an investment bank that offers investment advice. The private company is located in Bermuda.	Investment Managers
EBEWE Pharma Ges.m.b.H. Nfg.KG EBEWE Pharma Ges.m.b.H. Nfg.KG Pharmaceuticals: MajorHealth Technology EBEWE Pharma Ges.m.b.H. Nfg.KG engages in the development and manufacture of injectable pharmaceutical specialties. The firm offers therapy solutions for colon, lung, breast, and prostate cancer. It also specializes in drug and pharmaceutical development, as well as preclinical studies. The company was founded in 1934 and is headquartered in Unterach am Attersee, Austria.	Pharmaceuticals: Major
Novartis Capital Corp. Novartis Capital Corp. Finance/Rental/LeasingFinance Novartis Capital Corp. engages in the manufacture of pharmaceutical products. The company is headquartered in East Hanover, NJ.	Finance/Rental/Leasing
Novartis Finance SA	Finance/Rental/Leasing
Sandoz GmbH Sandoz GmbH Pharmaceuticals: MajorHealth Technology Sandoz GmbH manufactures generic pharmaceuticals and biotechnological drugs. Its products includes bio-similars, inhalers, patches, injectables, and oral solids. The company was founded in 1946 and is headquartered in Kundl, Austria.	Pharmaceuticals: Major
Novartis Pharma AG Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland.	Pharmaceuticals: Major
Novartis Holding AG Novartis Holding AG Financial ConglomeratesFinance Part of Novartis AG, Novartis Holding AG is a Swiss healthcare company that provides solutions to address the evolving needs of patients worldwide. The private company is based in Basel, Switzerland. Novartis Holding specializes in Managed Access Programs and is committed to the discovery, development, and marketing of innovative products to improve the well-being of all Canadians. The company prides itself on its commitment to diversity and to nurturing an inclusive and inspiring environment.	Financial Conglomerates
Novartis UK Pension Scheme	Investment Managers
Novartis Investments SARL Novartis Investments SARL Financial ConglomeratesFinance Novartis Investments SARL is an investment holding company with interest in medicines and pharmaceuticals sector. The company was founded on July 05, 2002 and is headquartered in Luxembourg.	Financial Conglomerates
Novartis Investment Ltd.
Novartis Healthcare Pvt Ltd. Novartis Healthcare Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Novartis Healthcare Pvt Ltd. is an Indian company that manufactures and markets health care and nutritional products. The private company is based in Mumbai, India. The company was founded in 1997. The CEO is Sanjay Prabhakar Murdeshwar.	Pharmaceuticals: Major
Alcon Ophthalmika GmbH
Novartis Investment Ltd. (2120)
Novartis Services, Inc.
Sandoz Pvt Ltd. Sandoz Pvt Ltd. Pharmaceuticals: GenericHealth Technology Part of Novartis AG, Sandoz Pvt Ltd. is an Indian company that develops, manufactures and markets generic pharmaceutical products. The private company is based in Mumbai, India and was founded in 1995.	Pharmaceuticals: Generic
Novartis Pharma GmbH Novartis Pharma GmbH Pharmaceuticals: MajorHealth Technology Novartis Pharma GmbH engages in the production and sale of pharmaceutical products. The firm establishes and operates institutes for the development of medicinal products. It also conducts research and development in the field of pharmacy. The company was founded by Johann Rudolf Geigy-Gemuseus in 1758 and is headquartered in Vienna, Austria.	Pharmaceuticals: Major

Trading rating

Beleggingsrating

ESG Refinitiv

B-

Meer adviezen

Verkoop

Koop

Gemiddeld advies

Accumuleren

Aantal analisten

Laatste slotkoers

98,55 USD

Gemiddelde koersdoel

108,2 USD

Spread / Gemiddelde doel

+9,81%

Consensus

Bedrijfscijfers

De agenda van het bedrijf

Gezondheidszorg

Farmaceutisch en medisch onderzoek

Farmaceutische producten

Farmaceutische producten

Farmaceutische producten - Andere

	Vaira. 1 jan.	Kapi.
NOVARTIS AG	+5,27%	201 mld.
NOVO NORDISK A/S	+25,11%	556 mld.
JOHNSON & JOHNSON	-6,33%	354 mld.
MERCK & CO., INC.	+19,90%	331 mld.
ABBVIE INC.	+7,95%	296 mld.
ASTRAZENECA PLC	+12,89%	233 mld.
ROCHE HOLDING AG	-10,31%	193 mld.
PFIZER, INC.	-12,26%	143 mld.
AMGEN INC.	-6,47%	144 mld.
SANOFI	+0,53%	123 mld.

Farmaceutische producten - Andere